Literature DB >> 32099991

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.

Jordan E Lake1, Kunling Wu2, Sara H Bares3, Paula Debroy1, Catherine Godfrey4, John R Koethe5, Grace A McComsey6, Frank J Palella7, Katherine Tassiopoulos8, Kristine M Erlandson9.   

Abstract

BACKGROUND: Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain. Whether similar gains are seen after switch to INSTIs among virologically suppressed persons is less clear. We assessed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322).
METHODS: Participants who were in follow-up from 1997-2017 and switched to INSTI-based antiretroviral regimens were included. Piecewise linear mixed-effects models adjusting for age, sex, race/ethnicity, baseline BMI, nadir and current CD4+ T-cell count, smoking, diabetes and follow-up time with suppressed HIV-1 RNA examined weight and waist circumference change before and after first switch to INSTIs. Linear spline models with a single knot at time of switch accounted for nonlinear trends.
RESULTS: The 972 participants who switched to INSTIs were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512 cells/μL, and BMI 26.4 kg/m2. Restricting to persons with suppressed HIV-1 RNA at switch (n = 691), women, blacks, and persons ≥60 years experienced greater weight gain in the 2 years after versus before switch. In adjusted models, white or black race, age ≥60, and BMI ≥30 kg/m2 at switch were associated with greater weight gain following switch among women; age ≥60 was the greatest risk factor among men. Trends for waist circumference were similar.
CONCLUSIONS: Yearly weight gain increased following switch to INSTIs, particularly for women, blacks, and persons aged ≥60. Concomitant increases in waist circumference suggest that this weight gain is associated with an increase in fat mass.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV dolutegravir; integrase inhibitor; weight gain; women

Mesh:

Substances:

Year:  2020        PMID: 32099991      PMCID: PMC7713693          DOI: 10.1093/cid/ciaa177

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

Review 1.  Anatomy and regulation of the central melanocortin system.

Authors:  Roger D Cone
Journal:  Nat Neurosci       Date:  2005-05       Impact factor: 24.884

2.  Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution.

Authors:  C T Montague; J B Prins; L Sanders; J E Digby; S O'Rahilly
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

3.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

4.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

5.  Sexual dimorphism in plasma leptin concentration.

Authors:  M F Saad; S Damani; R L Gingerich; M G Riad-Gabriel; A Khan; R Boyadjian; S D Jinagouda; K el-Tawil; R K Rude; V Kamdar
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

6.  Sexually different actions of leptin in proopiomelanocortin neurons to regulate glucose homeostasis.

Authors:  Haifei Shi; April D Strader; Joyce E Sorrell; James B Chambers; Stephen C Woods; Randy J Seeley
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-01-02       Impact factor: 4.310

7.  Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot.

Authors:  Paula Debroy; Myung Sim; Kristine M Erlandson; Julian Falutz; Carla M Prado; Todd T Brown; Giovanni Guaraldi; Jordan E Lake
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

8.  Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.

Authors:  Tinh-Hai Collet; Béatrice Dubern; Jacek Mokrosinski; Hillori Connors; Julia M Keogh; Edson Mendes de Oliveira; Elana Henning; Christine Poitou-Bernert; Jean-Michel Oppert; Patrick Tounian; Florence Marchelli; Rohia Alili; Johanne Le Beyec; Dominique Pépin; Jean-Marc Lacorte; Andrew Gottesdiener; Rebecca Bounds; Shubh Sharma; Cathy Folster; Bart Henderson; Stephen O'Rahilly; Elizabeth Stoner; Keith Gottesdiener; Brandon L Panaro; Roger D Cone; Karine Clément; I Sadaf Farooqi; Lex H T Van der Ploeg
Journal:  Mol Metab       Date:  2017-07-08       Impact factor: 7.422

9.  Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.

Authors:  Anne Marie Kerchberger; Anandi N Sheth; Christine D Angert; C Christina Mehta; Nathan A Summers; Ighovwerha Ofotokun; Deborah Gustafson; Sheri D Weiser; Anjali Sharma; Adaora A Adimora; Audrey L French; Michael Augenbraun; Jennifer Cocohoba; Seble Kassaye; Hector Bolivar; Usha Govindarajulu; Deborah Konkle-Parker; Elizabeth T Golub; Cecile D Lahiri
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

10.  Adipose tissue resting energy expenditure and expression of genes involved in mitochondrial function are higher in women than in men.

Authors:  Intawat Nookaew; Per-Arne Svensson; Peter Jacobson; Margareta Jernås; Magdalena Taube; Ingrid Larsson; Johanna C Andersson-Assarsson; Lars Sjöström; Philippe Froguel; Andrew Walley; Jens Nielsen; Lena M S Carlsson
Journal:  J Clin Endocrinol Metab       Date:  2012-12-21       Impact factor: 5.958

View more
  29 in total

Review 1.  Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course.

Authors:  Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier
Journal:  Curr HIV/AIDS Rep       Date:  2021-01-05       Impact factor: 5.071

2.  Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.

Authors:  Paula Debroy; Jordan E Lake; Carlee Moser; Maxine Olefsky; Kristine M Erlandson; Ann Scherzinger; James H Stein; Judith S Currier; Todd T Brown; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

3.  Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.

Authors:  Herieth Ismael Wilson; Herry Mapesi
Journal:  Pan Afr Med J       Date:  2020-11-17

Review 4.  Metabolic Consequences of Antiretroviral Therapy.

Authors:  Caroline E Diggins; Samuel C Russo; Janet Lo
Journal:  Curr HIV/AIDS Rep       Date:  2022-03-17       Impact factor: 5.071

5.  Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era.

Authors:  Gabriel Spieler; Andrew O Westfall; Dustin M Long; Andrea Cherrington; Greer A Burkholder; Nicholas Funderburg; James L Raper; Edgar T Overton; Amanda L Willig
Journal:  AIDS       Date:  2022-08-10       Impact factor: 4.632

6.  Changes in central adipose tissue after switching to integrase inhibitors.

Authors:  Paula Debroy; Han Feng; Hongyu Miao; Jovana Milic; Guido Ligabue; Stefano Draisci; Giulia Besutti; Federica Carli; Marianna Menozzi; Cristina Mussini; Giovanni Guaraldi; Jordan E Lake
Journal:  HIV Res Clin Pract       Date:  2021-01-18

Review 7.  Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.

Authors:  Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

8.  Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.

Authors:  Maj David A Kline; Colton Daniels; Xiaohe Xu; Thankam Sunil; Anuradha Ganesan; Brian K Agan; Rhonda E Colombo; Karl C Kronmann; Jason M Blaylock; Jason F Okulicz; A Elizabeth Markelz
Journal:  Mil Med       Date:  2021-02-26       Impact factor: 1.437

9.  Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.

Authors:  Bruno Emond; Carmine Rossi; Aurélie Côté-Sergent; Keith Dunn; Patrick Lefebvre; Marie-Hélène Lafeuille; Prina Donga
Journal:  J Health Econ Outcomes Res       Date:  2021-06-14

10.  Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort.

Authors:  Wei Li A Koay; Sahera Dirajlal-Fargo; Matthew E Levy; Paige Kulie; Anne Monroe; Amanda D Castel; Natella Y Rakhmanina
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.